AAA shifts focus on SPECT and therapeutics to accelerate radiopharma growth
This article was originally published in Clinica
Executive Summary
The global nuclear medicine market is, and has been, dominated by the developers of capital-intensive imaging equipment, giants such as GE, Philips and Siemens who pour millions into R&D programmes in a bid to churn out innovations and set new trends.